ACGH Profile Centering: Array-CGH log2 ratios carry information about relative copy number between regions but cannot determine absolute copy number. Therefore the data must be centered to a level which is considered "functionally euploid". After CBS segmentation, "segment-smoothed" profiles are generated by replacing the raw log2 ratio at each probe location with the mean of all neighboring probes in the same segment ( 
AFI score: Aberration Focality Index measures what proportion of the ARI score is distributed per potential target genes or other genetic elements spanned by the region. AFI is the ratio of a focality-weighted ARI to unweighted ARI (fwARI/ARI). As with ARI, AFI is calculated for each genomic position, separately for gain and loss samples. Focality weighting is performed with a conceptual model for the biological process of amplification and deletion that incorporates two fundamental aspects: (1) that CNA can progress in stage-wise fashion with progressive accumulation of extra copies associated with narrowing of the altered region, and (2) that DNA rearrangement within and across chromosomes may join nonadjacent sequence or delete intervening sequence such that a single amplicon may include non-contiguous genomic regions and be falsely represented as distinct CNAs in the aCGH profile. We consider three models for potential linkage of CNA across the profile: local, chromosomal and genomic. Local linkage treats each group of adjacent gained (or lost) segments as a contiguous discrete amplicon (or deletion) implying that the target genetic elements are spanned by the group of adjacent segments; Chromosome linkage considers that non-adjacent CNAs within the same chromosome represent a single amplicon (or deletion) with a shared set of targets. Genome linkage treats all CNA as if it belongs to a single complex amplicon (or deletion). Genome linkage is a conservative model, though not likely to be biologically accurate in most cases. Chromosomal linkage models the formation of amplicons with internal deletion, such as the co-amplification of CDK4 and MDM2 which typically excludes the adjoining region. Chromosomal linkage was used for the analysis in this study. Calculation of AFI is as follows: In addition, intensity of staining was scored as 0 to 3 for absent, weak, moderate and strong (Supplemental Table S4 ). Since normal brain cores were scored 0 or 1 for both proteins, cores with scores of 0 or 1 were assigned a "negative" call for expression. Staining intensities of all negative cores were considered weak or absent. While duplicate cores from the same tumor generally received the same call (positive or negative), in the case of p18 INK4C , cores from 4 cases were assigned different calls. Since basis for such this discordance cannot be determined and may be due to technical or biological variation (such as intratumoral heterogeneity), each core was considered an independent sample for this analysis. In parallel, these TMA sections were scanned by iCys laser scanning cytometer and analyzed to provide quantitative percentage of cells in each core that exhibited immunoreactivity.
Competitive PCR analysis of the genomic status of p16 INK4A and p18
INK4C
Competitive PCR was carried out for all exons of p16 INK4A and p18 INK4C to identify homozygous deletions. Between four and eight primer pairs were designed to each exon before being tested against a series of twenty control primer pairs. For each exon the combination that gave the best multiplex PCR result with products of equal intensity was then used to screen the core cell line set. Single exon deletions of ARF exon 1 and p16 INK4A exon 1 were confirmed using a different primer set in a non-multiplex assay. PCR conditions are listed in Methods and primer sequences are listed in Supplemental (determined by RT-qPCR relative to GAPDH, error bars represent mean ± standard deviation) remained low in resultant tumors, confirming selection for inactivation of p18 Ink4c during tumorigenesis. Table S1 : Signature mutations in our dataset of GBM tumors and cell lines (Furnari et al., 1997; Ishii et al., 1999) . number of genes showing copy number-driven expression (column 11), known cancer genes in the MCR (column 12, GBM signature genes in bold) and published copy number polymorphisms (CNP) in that region (column 13 (Conrad et al., 2006; Hinds et al., 2006; Iafrate et al., 2004; McCarroll et al., 2006; Sebat et al., 2004; Sharp et al., 2005; Tuzun et al., 2005) ). 
